Please keep in touch with us to be informed about the results of our research activity.
 | Please follow us on @CLL_CLUE! |
PUBLICATIONS ACKNOWLEDGING CLL-CLUE
Lorenzovici L, Szilberhorn L, Farkas-Ráduly S, Gasparik AI, Precup AM, Nagy AG, Niemann CU, Aittokallio T, Kaló Z, Csanádi M. Systematic Literature Review of Economic Evaluations of Treatment Alternatives in Chronic Lymphocytic Leukemia. BioDrugs. 2023 Feb 16. doi: 10.1007/s40259-023-00583-9. Epub ahead of print. PMID: 36795353.
Data management plan for the trans-European ERA PerMed consortium CLL-CLUE: Tailoring the targeted treatment of chronic lymphocytic leukemia Sigrid S. Skånland1,2,*, Tero Aittokallio3,4,5, Barbara Eichhorst6, Laszlo Lorenzovici7, Junyan Lu8, Carsten U. Niemann9, Thorsten Zenz10,11, on behalf of the CLL-CLUE consortium
Skånland SS, Brown JR. PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here? Haematologica. 2023 Jan 1;108(1):9-21. doi: 10.3324/haematol.2022.281266. PMID: 35899388; PMCID: PMC9827175.
Giliberto M, Santana LM, Holien T, Misund K, Nakken S, Vodak D, Hovig E, Meza-Zepeda LA, Coward E, Waage A, Taskén K, Skånland SS. Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines. Front Oncol. 2022 Nov 29;12:1040730. doi: 10.3389/fonc.2022.1040730. PMID: 36523963; PMCID: PMC9745900.
Flobak Å, Skånland SS, Hovig E, Taskén K, Russnes HG. Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models. Trends Pharmacol Sci. 2022 Nov;43(11):973-985. doi: 10.1016/j.tips.2022.08.009. Epub 2022 Sep 23. PMID: 36163057.
Aronson JH, Skånland SS, Roeker LE, Thompson MC, Mato AR. Approach to a patient with “double refractory” chronic lymphocytic leukemia: “Double, double toil and trouble” (Shakespeare). Am J Hematol. 2022 Nov;97 Suppl 2:S19-S25. doi: 10.1002/ajh.26682. PMID: 36125036.
Fürstenau M, Weiss J, Giza A, Franzen F, Robrecht S, Fink AM, Fischer K, Schneider C, Tausch E, Stilgenbauer S, Ritgen M, Schilhabel A, Brüggemann M, Eichhorst B, Hallek M, Cramer P. Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax. Clin Cancer Res. 2022 Oct 3;28(19):4203-4211. doi: 10.1158/1078-0432.CCR-22-0433. PMID: 35594173.
Yin Y, Athanasiadis P, Karlsen L, Urban A, Xu H, Murali I, Fernandes SM, Arribas AJ, Hilli AK, Taskén K, Bertoni F, Mato AR, Normant E, Brown JR, Tjønnfjord GE, Aittokallio T, Skånland SS. Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2022 Oct 14;28(20):4444-4455. doi: 10.1158/1078-0432.CCR-22-1221. PMID: 35998013; PMCID: PMC9588626.
Skånland SS, Tjønnfjord GE. Determining drug dose in the era of targeted therapies: playing it (un)safe? Blood Cancer J. 2022 Aug 23;12(8):123. doi: 10.1038/s41408-022-00720-7. PMID: 35999205; PMCID: PMC9399108.
Imbery JF, Heinzelbecker J, Jebsen JK, McGowan M, Myklebust C, Bottini N, Stanford SM, Skånland SS, Tveita A, Tjønnfjord GE, Munthe LA, Szodoray P, Nakken B. T-helper cell regulation of CD45 phosphatase activity by galectin-1 and CD43 governs chronic lymphocytic leukaemia proliferation. Br J Haematol. 2022 Aug;198(3):556-573. doi: 10.1111/bjh.18285. Epub 2022 Jun 2. PMID: 35655388; PMCID: PMC9329260.
Skånland SS, Inngjerdingen M, Bendiksen H, York J, Spetalen S, Munthe LA, Tjønnfjord GE. Functional testing of relapsed chronic lymphocytic leukemia guides precision medicine and maps response and resistance mechanisms. An index case. Haematologica. 2022 Aug 1;107(8):1994-1998. doi: 10.3324/haematol.2021.280393. PMID: 35236056; PMCID: PMC9335086.
Kong W, Midena G, Chen Y, Athanasiadis P, Wang T, Rousu J, He L, Aittokallio T. Systematic review of computational methods for drug combination prediction. Comput Struct Biotechnol J. 2022 Jun 1;20:2807-2814. doi: 10.1016/j.csbj.2022.05.055. PMID: 35685365; PMCID: PMC9168078.
Parviz M, Brieghel C, Agius R, Niemann CU. Prediction of clinical outcome in CLL based on recurrent gene mutations, CLL-IPI variables, and (para)clinical data. Blood Adv. 2022 Jun 28;6(12):3716-3728. doi: 10.1182/bloodadvances.2021006351. PMID: 35468622; PMCID: PMC9631547.
Athanasiadis P, Ianevski A, Skånland SS, Aittokallio T. Computational Pipeline for Rational Drug Combination Screening in Patient-Derived Cells. Methods Mol Biol. 2022;2449:327-348. doi: 10.1007/978-1-0716-2095-3_14. PMID: 35507270.
Ianevski A, Giri AK, Aittokallio T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 2022 May 17;50(W1):W739–43. doi: 10.1093/nar/gkac382. Epub ahead of print. PMID: 35580060; PMCID: PMC9252834.
Melvold K, Giliberto M, Karlsen L, Ayuda-Durán P, Hanes R, Holien T, Enserink J, Brown JR, Tjønnfjord GE, Taskén K, Skånland SS. Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies. Mol Oncol. 2022 Mar;16(5):1153-1170. doi: 10.1002/1878-0261.13153. Epub 2021 Dec 18. PMID: 34861096; PMCID: PMC8895453.
He L, Bulanova D, Oikkonen J, Häkkinen A, Zhang K, Zheng S, Wang W, Erkan EP, Carpén O, Joutsiniemi T, Hietanen S, Hynninen J, Huhtinen K, Hautaniemi S, Vähärautio A, Tang J, Wennerberg K, Aittokallio T. Network-guided identification of cancer-selective combinatorial therapies in ovarian cancer. Brief Bioinform. 2021 Nov 5;22(6): bbab272. doi: 10.1093/bib/bbab272. PMID: 34343245; PMCID: PMC8574973.
This work is supported by a grant of:
| The Research Council of Norway (RCN) | Academy of Finland, (AKA) | German Federal Ministry of Education and Research (BMBF) | Innovation Fond Denmark, IFD | Romanian National Authority for Scientific Research and Innovation, CCDI – UEFISCDI, project number ERANET-PERMED-CLL-CLUE 196, within PNCDI III |
 |  |  |  |  |